BBI
NASDAQBrickell Biotech Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Latest news
25 items- PRSpruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Floor & Decor Holdings, Inc. (NYSE: FND)NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Believes That Floor & Decor's Ballooning Capital Expenditures and New Store Operating Costs in Lower Income and New Geographic Markets Will Severely Impair its Earnings Potential Identifies at Least Ten Other Areas of Misperception That Suggest Floor & Decor's Challenges Are Structural and Are Not Cyclical or Easily Fixed Provides Evidence That Floor & Decor Recently Made Revisions to Key Revenue Claims, Numerous Omissions of Past Disclosures, Changes to Accounting Policy Language and Modifications to Business Practices That Obscure its Growing Challenges Provides Evidence That CEO Thom
- SECSEC Form 10-Q filed by Brickell Biotech Inc.10-Q - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
- SECBrickell Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
- SECBrickell Biotech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
- PRFresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it has initiated the multiple ascending dose ("MAD") portion of the ongoing Phase 1 clinical trial
- SECSEC Form EFFECT filed by Brickell Biotech Inc.EFFECT - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
- SECBrickell Biotech Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
- NEWSBrickell Biotech's Return On Capital Employed InsightsAccording to data from Benzinga Pro, during Q2, Brickell Biotech's (NASDAQ:BBI) reported sales totaled $4.32 million. Despite a 87.81% increase in earnings, the company posted a loss of $1.15 million. In Q1, Brickell Biotech brought in $92 thousand in sales but lost $9.41 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Bricke
- PRBrickell Biotech Announces Corporate Rebranding to Fresh Tracks TherapeuticsNew name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol "FRTX" on September 8, 2022 Company also establishes Scientific Advisory Board consisting of renowned autoimmune and inflammatory disease experts to provide strategic guidance for the research and development of FRTX's novel pipeline BOULDER, Colo., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI) today announced that it has changed its name to Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company"). The new name, logo, website, and brand
- SECSEC Form DEL AM filed by Brickell Biotech Inc.DEL AM - Brickell Biotech, Inc. (0000819050) (Filer)
- SECSEC Form S-1 filed by Brickell Biotech Inc.S-1 - Brickell Biotech, Inc. (0000819050) (Filer)
- NEWSBrickell Biotech Has Received A Notice Of Allowance For Its Us Patent Application 17/105,376 Titled "Crystalline Form Of Sofpironium Bromide And Preparation Method Thereof (For The Treatment Of Hyperhidrosis)".https://twitter.com/PatentGrants/status/1565734028765892610 https://patentcenter.uspto.gov/applications/17105376/ifw/docs
- NEWSAudit Committee Said Interim Financial Statements In Co's Report For Qtr Ended June 30, 2022 Should No Longer Be Relied Upon- Reuters
- SECSEC Form 10-Q/A filed by Brickell Biotech Inc. (Amendment)10-Q/A - Brickell Biotech, Inc. (0000819050) (Filer)
- SECBrickell Biotech Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review8-K - Brickell Biotech, Inc. (0000819050) (Filer)
- SECBrickell Biotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Brickell Biotech, Inc. (0000819050) (Filer)
- SECSEC Form 10-Q filed by Brickell Biotech Inc.10-Q - Brickell Biotech, Inc. (0000819050) (Filer)
- NEWSBrickell Biotech Q2 EPS $(0.01) Up From $(0.16) YoY, Sales $4.32M Beat $3.13M EstimateBrickell Biotech (NASDAQ:BBI) reported quarterly losses of $(0.01) per share. This is a 93.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $4.32 million which beat the analyst consensus estimate of $3.13 million by 37.86 percent. This is a 2.76K percent increase over sales of $151.00 thousand the same period last year.
- SECBrickell Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Brickell Biotech, Inc. (0000819050) (Filer)
- PRBrickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePhase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the second qua
- NEWSEarnings Scheduled For August 11, 2022Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE:DDL) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ:EVLO) is projected to report earnings for its second quarter. • Affimed (NASDAQ:AFMD) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE:CORR) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE:SIX) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ:WFCF) is projected to report earn
- NEWSThis Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From YesterdayGainers Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. ECMOHO Limited (NASDAQ:MOHO) jumped 146.1% to settle at $0.4085 on above-average volume. Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares climbed 145.3% to close at $1.58 on Wednesday after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ:KSPN) jumped 140.3% to close at $6.20. Enveric Biosciences, Inc. (NASDAQ:ENVB) gained 106% to settle at $13.10. Enveric Biosciences recently announced an $8 million registered direct offering and private placement. Heart Test Laboratories, Inc. (NASDAQ:HSCS) jumped 89.6% to close at $3.28. Poseida Therapeutics
- PRBrickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights. To access the call, please dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international) and provide the conferenc
- SECBrickell Biotech Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Brickell Biotech, Inc. (0000819050) (Filer)
- NEWSTen Stocks Trending on Discord for for Friday July 22, 2022: TSLA, SNAP, TBLT, STX, AMZN, BBI, ISRG, TWTR, GME, NVDA
BBI FAQ
6 questionsWhat does Brickell Biotech Inc. do?
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.Where does BBI stock trade?
Brickell Biotech Inc. (BBI) is listed on NASDAQ.What sector and industry is BBI in?
Brickell Biotech Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about BBI?
Brickell Biotech Inc. has had 2 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2022-03-08. Recent price targets cluster around $200.00.What companies are similar to BBI?
Notable peers in the same industry include LEGN (Legend Biotech Corporation), SQZ (SQZ Biotechnologies Company), PRTG (Portage Biotech Inc.), PDSB (PDS Biotechnology Corporation), EDSA (Edesa Biotech Inc.). Compare BBI side-by-side with any of them on Quantisnow.How can I track BBI on Quantisnow?
Quantisnow aggregates Brickell Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BBI to receive live email and push alerts on every new disclosure.